This inventor holds 1 USPTO granted patent and 5 published patent applications. Top assignee: Amgen Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: The Innovations of Ingrid Rulifson
Introduction
Ingrid Rulifson is a prominent inventor based in Palo Alto, California. She has made significant contributions to the field of biotechnology, particularly in the area of RNA interference (RNAi) technology. Her work focuses on developing innovative solutions for treating liver diseases, including nonalcoholic fatty liver disease (NAFLD).
Latest Patents
Ingrid Rulifson holds a patent for "RNAI constructs for inhibiting PNPLA3 expression and methods of use thereof." This invention relates to RNAi constructs designed to reduce the expression of the PNPLA3 gene. The methods described in her patent aim to treat or prevent liver disease, showcasing her commitment to advancing medical science.
Career Highlights
Rulifson is currently associated with Amgen Inc., a leading biotechnology company known for its focus on innovative therapies. Her role at Amgen allows her to collaborate with other experts in the field and contribute to groundbreaking research.
Collaborations
Ingrid has worked alongside notable colleagues, including Justin K. Murray and Michael Ollmann. These collaborations have further enhanced her research and development efforts in the biotechnology sector.
Conclusion
Ingrid Rulifson's contributions to RNAi technology and her innovative patent demonstrate her dedication to improving healthcare outcomes. Her work continues to inspire advancements in the treatment of liver diseases.